Sanofi’s Sarclisa (isatuximab) has been approved by the Medicines and Healthcare product Regulatory Agency (MHRA) as part of a combination treatment for newly diagnosed multiple myeloma (MM).

Days after the European Commission (EC) granted approval, the UK’s Medicines and Healthcare Regulatory Agency (MHRA) has ...

The Board of Directors met on January 29, 2025; proposes a dividend of EUR 3.92 for 2024, 30th year of consecutive increasesInvest with ...

Intention to sell a controlling stake in Opella consumer health at an attractive valuation; closing in Q2 2025 at the earliest.Invest with ...